Use of data to drive pneumococcal conjugate vaccine policy

Lancet Infect Dis. 2018 Apr;18(4):366-368. doi: 10.1016/S1473-3099(18)30054-9. Epub 2018 Jan 26.

Authors

Tamara Pilishvili¹, Cynthia G Whitney²

Affiliations

¹ Respiratory Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
² Respiratory Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA. Electronic address: cwhitney@cdc.gov.

PMID: 29396002
DOI: 10.1016/S1473-3099(18)30054-9

No abstract available

Publication types

Comment

MeSH terms

Cohort Studies
England
Humans
Pneumococcal Infections*
Pneumococcal Vaccines
Prospective Studies
Serogroup*
Vaccines, Conjugate
Wales

Substances

Pneumococcal Vaccines
Vaccines, Conjugate